Contract analysis

I. Executive Summary This memorandum analyzes the economic substance doctrine as applied in the transfer pricing context and the DEMPE framework — encompassing the functions of Development, Enhancement, Maintenance, Protection, and Exploitation — under the OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (2017 edition, as revised in 2022), with specific application to the IRS's a

II. Background Facts Relevant to the Analysis The following factual summary is based on a review of corporate organizational documents, intercompany agreements, PBI board minutes, PPC and PBI financial statements, the CSA and amendments thereto, PBI human-resources records, regulatory filing documentation, and discussions with PPC's in-house tax department (Vice President of Tax, Margaret Reyes). This summary will be

III. Legal Framework: The Economic Substance Doctrine A. Codification Under IRC § 7701(o) The economic substance doctrine was codified by the Health Care and Education Reconciliation Act of 2010, Pub. L. No. 111-152, § 1409, 124 Stat. 1029, 1067-70 (2010), which added section 7701(o) to the Internal Revenue Code. Section 7701(o) provides that, in the case of any transaction to which the economic substance doctrine is

Section 7701(o)(5)(C) provides that the determination of whether the economic substance doctrine is "relevant" to a transaction is made in the same manner as if § 7701(o) had never been enacted. This provision preserves the pre-codification analytical framework for determining when the doctrine applies in the first instance, while standardizing the two-prong test that applies once the doctrine is found to be relevant

1. Altera Corp. v. Commissioner (9th Cir. 2019) In Altera Corp. v. Commissioner, 941 F.3d 1200 (9th Cir. 2019) (en banc), cert. denied, 141 S. Ct. 131 (2020), the Ninth Circuit addressed whether Treasury Regulation § 1.482-7(d)(2), which requires that stock-based compensation costs be included in the cost pool of a qualified cost-sharing arrangement, was a valid exercise of the Treasury Department's rulemaking author

2. Harborview Corporation, Inc. v. Commissioner (8th Cir. 2022; T.C. Memo. 2016-112, remanded) Harborview Corporation, Inc. v. Commissioner is among the most significant transfer pricing decisions in recent years. The case addressed the appropriate transfer pricing method for royalties paid by Harborview Corporation's Puerto Rico manufacturing subsidiary (MPROC) to Harborview Corporation's U.S. parent for the right t

3. Hollowell & Co. v. Commissioner (T.C. Memo. 2017-25) In Hollowell & Co. v. Commissioner, T.C. Memo. 2017-25, the Tax Court addressed the valuation of a platform contribution transaction ("PCT") payment made by Amazon's Luxembourg subsidiary (Axomrel Europe Holding Technologies SCS, "AEHT") to Hollowell & Co. in connection with a cost-sharing arrangement. The IRS challenged the PCT valuation, arguing that the taxpa

4. Tarrant Group v. Commissioner (T.C. Memo. 2009-281) In Tarrant Group v. Commissioner, T.C. Memo. 2009-281, the Tax Court addressed the valuation of a cost-sharing buy-in payment in connection with a qualified CSA between Veritas Software Corporation and its Irish subsidiary, Veritas Ireland. The IRS challenged the taxpayer's buy-in valuation and proposed a significantly higher payment. The court ultimately determi

5. Guidant LLC v. Commissioner (T.C. Memo. 2021-46) In Guidant LLC v. Commissioner, T.C. Memo. 2021-46, the Tax Court examined the transfer pricing of a medical device manufacturer's intercompany transactions with its foreign affiliates. The court analyzed the functions performed by the foreign entities and assessed whether the foreign entities' functional profiles were consistent with their contractual roles and the

IV. The DEMPE Framework Under OECD Transfer Pricing Guidelines A. Overview of DEMPE The OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations (2017 edition, as subsequently updated in 2022) provide the internationally recognized framework for the analysis of transfer pricing in controlled transactions. Chapter VI of the OECD Guidelines addresses "Special Considerations for Intangibles

1. Development. Definition. Under the OECD Guidelines, "Development" encompasses the research and development activities that lead to the creation of intangible property. In the pharmaceutical context, this includes basic research, drug discovery, preclinical studies, clinical trials (Phase I through Phase III), formulation development, process development, and related regulatory activities necessary to obtain market

2. Enhancement. Definition. "Enhancement" encompasses activities that improve, expand, or augment the value of existing intangible property. In the pharmaceutical context, this includes line extensions (new dosage forms, new routes of administration), new indication studies, reformulations, post-marketing clinical studies, and the generation of additional clinical data that supports expanded use or market access. PPC

3. Maintenance. Definition. "Maintenance" encompasses activities that preserve the value of intangible property over time. In the pharmaceutical context, this includes regulatory compliance (maintaining marketing authorizations, filing variations and renewals, responding to regulatory inquiries), pharmacovigilance (adverse event monitoring and reporting), quality control, and patent prosecution and renewal. PPC's Rol

4. Protection. Definition. "Protection" encompasses activities that defend intangible property rights against infringement, misappropriation, or dilution. In the pharmaceutical context, this includes patent enforcement and defense, trademark registration and defense, trade-secret protection, anti-counterfeiting measures, and related litigation and enforcement activities. PPC's Role. PPC manages global patent prosecut

5. Exploitation. Definition. "Exploitation" encompasses the commercialization and monetization of intangible property — the activities through which IP is converted into revenue. In the pharmaceutical context, this includes marketing, sales, pricing, market access, distribution, customer (healthcare provider and payer) relationships, and supply-chain management. PBI's Role. Exploitation is PBI's strongest DEMPE funct